39results about How to "Prolonged bleeding time" patented technology

An apparatus for treating tissue in a tissue treatment area includes a heater that does not contact the tissue. The apparatus may be attached to the skin of a person to form a treatment volume about the tissue to be treated. The heater, supported at the layer, is held near the tissue to be treated, out of contact with the tissue. The apparatus includes a controller to cause the heater to raise the temperature of tissue in the tissue treatment area to a temperature in a range from a pretreatment temperature to 38° C. The controller may include means that cause the heater to operate over a therapeutic sequence, that cycle the heater on and off, that provide selectable average temperature values, that cause the heater to operate over an average temperature range, that cause the heater to operate at an average temperature over a therapy cycle, or that cause the heater to operate at an average temperature over a therapeutic sequence.

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

The present invention discloses one kind of composite soft lutein capsule and its preparation process. The content in each capsule includes lutein1-10 mg, alpha-linolenic acid 100-300 mg, vitamin A 0-5 mg and vitamin E 0-7.5 mg; and the capsule covering consists of gelatin, glycerin, water, and opacifier or edible color. The lutein is prepared through supercritical CO2 extraction process, and has no pollutant and organic solvent residue. The composite soft lutein capsule product has stable quality and high bioavailability, and has certain preventing and treating effect on senile macular degeneration, cataract and cardiac and cerebral vascular diseases.

The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).

A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated.

A composite Chinese medicine with high curative effect and low toxic by-effect is prepared from ginseng and gingko leaf in weight ratio of 1:2.

The invention belongs to the technical field of medical instruments, and particularly relates to an aorta blocking balloon device based on 18F-FDG detection and positioning, which comprises a catheter, a balloon is arranged at the front end of the catheter, an injection tube communicated with the balloon penetrates through the interior of the catheter, and an injector communicated with the injection tube is arranged at the rear end of the catheter; before aorta blocking hemostasis is executed, the device can assist in determining the general anatomical orientation of the balloon in the body and increasing the success rate of disposable balloon blocking, and has the following advantages that firstly, the device has lower requirements on the technical ability and experience of first-aid implementers, and can be mastered according to program operation after simple training; secondly, the 18F-FDG is a common medical medicament, the availability and the medication cost can be controlled, and correspondingly, the handheld gamma ray detector for detecting the 18F-FDG is relatively low in cost; the technical operation procedure is simple, and the risk of additionally increasing bleeding time is small; fourthly, the half-life period of 18F is short, and secondary injury to patients is small.

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

The invention relates to a hexadecapeptide compound and a preparation method and application thereof. The polypeptide sequence of the hexadecapeptide compound is one or more of RTGACFCVIYNGILYP, or the sequence with the 1-site amino acid R replaced by K, the sequence with the 2-site amino acid T replaced by S, the sequence with the 8-site amino acid V replaced by I or L, the sequence with the 9-site amino acid I replaced by V or L, the sequence with the 11-site amino acid N replaced by Q, the sequence with the 13-site amino acid I replaced by V or L, and the sequence with the 14-site amino acid L replaced by V or I. The hexadecapeptide compound has the functions of prolonging bleeding time, remarkably inhibiting platelet aggregation, and preventing thrombosis, has low toxicity, and has broad application prospects in preparing anti-platelet aggregation or antithrombotic drugs, drug components or prodrugs. The preparation method has high yield and simple process.

The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.

The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.

The invention discloses application of a heparin iron compound in treatment of chronic inflammatory anemia. The heparin iron nano-compound is proved to have effects of obviously reducing hepcidin content, increasing hemoglobin level in an inflammatory anemia model, significantly lowering the transcription of the hepcidin in HepG2 cells at a lower concentration, and reducing the anticoagulant activity of the hepcidin. The heparin iron nano-compound is prepared and is safely applied to the treatment of the inflammatory anemia taking the hepcidin as a target, and the bleeding risk is avoided.

The invention belongs to the field of medical immunity, and provides a sulfated Lachnum extracellular polysaccharide and application thereof in anticoagulant drugs. The sulfated Lachnum extracellular polysaccharide is prepared by carrying out sulfur trioxide-pyridine composite sulfation modification on Lachnum polysaccharide LEP-1 which is secreted and extracted from Lachnum YM281. The pharmacological experiment proves that the sulfated Lachnum extracellular polysaccharide has prolonging actions on mouse bleeding time (BT) and mouse coagulation time (CT) under the conditions of both low dose (30 mg / kg) and high dose (90 mg / kg), which indicates that the sulfated Lachnum extracellular polysaccharide has an anticoagulation action, thereby providing a new way for anticoagulation research.

The present invention discloses one kind of composite soft lutein capsule and its preparation process. The content in each capsule includes lutein1-10 mg, alpha-linolenic acid 100-300 mg, vitamin A 0-5 mg and vitamin E 0-7.5 mg; and the capsule covering consists of gelatin, glycerin, water, and opacifier or edible color. The lutein is prepared through supercritical CO2 extraction process, and has no pollutant and organic solvent residue. The composite soft lutein capsule product has stable quality and high bioavailability, and has certain preventing and treating effect on senile macular degeneration, cataract and cardiac and cerebral vascular diseases.

The invention relates to the field of traditional Chinese medicine, that is, a thrombus-tongmai medicine, a preparation method and a content determination method, which are used for treating cerebral thrombosis. It is made from astragalus, earthworm, ground beetle, leech, peach kernel, chuanxiong, tangerine, angelica, and spatholobus according to the specified amount, and has a good effect on treating cardiovascular and cerebrovascular diseases. The experimental results showed that the blood serum containing Xueshuan Tongmai Capsules could significantly increase H 2 o 2 (hydrogen peroxide) treated HUVEC cell viability, decreased LDH, MDA, ROS content, and increased GSH (glutathione), NO (nitric oxide), SOD (superoxide dismutase) content, suggesting that Xueshuantong The medicated serum in Mai capsule has the ability to protect vascular endothelial cells from oxidative damage. Xueshuan Tongmai Capsules can significantly inhibit the formation of thrombus in SD rats in vivo and in vitro, and the inhibitory effect is enhanced with the increase of the dose, and the effect of the high-dose group is better than that of the low-dose group.

The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.

The invention relates to application of a campsis radicans polysaccharide, in particular to application of a campsis radicans polysaccharide to the preparation of anticoagulant medicines. The action of the campsis radicans polysaccharide on the blood coagulation time of capillaries and bleeding time of tail tips of mice is measured by intracorporeal administration; and the influence of the campsis radicans polysaccharide on the thrombin time, prothrombin time, active part thromboplastin time and plasma recalcification time of the mice is measured. Anticoagulation experiments indicate that thecampsis radicans polysaccharide can prolong the blood coagulation time of the capillaries and bleeding time of the tail tips of the mice obviously, and prolong the thrombin time, prothrombin time andplasma recalcification time of the mice obviously, and display that the activity of exogenous blood coagulation factors is inhibited, so that the generation of hemaleucin is inhibited, and the thrombin time is prolonged obviously. Experiment results prove that the campsis radicans polysaccharide has an obvious anticoagulation effect.